Ascendis continued big investments into 2021, driving operating deficit up

Ramped up investing into sales and research helped drive up the operational deficit at biotech firm Ascendis Pharma. Even so, the company’s 2021 growth matched that of recent years.
Photo: Kevin Grønnemann / MedWatch
Photo: Kevin Grønnemann / MedWatch
by ANDREAS LØNSTRUP, translated by daniel pedersen

Danish biotech company Ascendis Pharma, which is listed in the US, continued on its growth track in 2021, booking a revenue of EUR 7.8m compared to preceding year’s EUR 7.8m, the company’s full-year report states.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading